Revance Therapeutics, Inc. (RVNC)
Largest Insider Buys in Sector
RVNC Stock Price History Chart
RVNC Stock Performance
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral …
Insider Activity of Revance Therapeutics, Inc.
Over the last 12 months, insiders at Revance Therapeutics, Inc. have bought $209,400 and sold $160,014 worth of Revance Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Revance Therapeutics, Inc. have bought $629,471 and sold $5.33M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Foley Mark J (CEO) — $418,800.
The last purchase of 30,000 shares for transaction amount of $209,400 was made by Foley Mark J (CEO) on 2024‑03‑06.
List of Insider Buy and Sell Transactions, Revance Therapeutics, Inc.
| 2024-11-18 | Sale | CMO & Global Therapeutics Lead | 3,908 0.0039% | $4.17 | $16,296 | -10.19% | ||
| 2024-04-16 | Sale | Chief Commercial Officer | 2,392 0.0023% | $3.80 | $9,096 | -0.26% | ||
| 2024-03-18 | Sale | CFO | 9,361 0.0092% | $5.04 | $47,204 | -19.74% | ||
| 2024-03-18 | Sale | President | 9,211 0.009% | $5.04 | $46,446 | -19.74% | ||
| 2024-03-18 | Sale | CLO & GC | 8,125 0.008% | $5.04 | $40,971 | -19.74% | ||
| 2024-03-06 | CEO | 30,000 0.0377% | $6.98 | $209,400 | -35.09% | |||
| 2023-09-06 | Sale | SVP, GC & Secretary | 11,000 0.0126% | $17.06 | $187,704 | -64.86% | ||
| 2023-09-05 | Sale | SVP, GC & Secretary | 23,853 0.0276% | $17.81 | $424,920 | -66.02% | ||
| 2023-08-03 | Sale | CEO | 26,279 0.0307% | $22.57 | $593,151 | -73.61% | ||
| 2023-07-03 | Sale | CEO | 26,279 0.0322% | $24.94 | $655,333 | -72.17% | ||
| 2023-07-03 | Sale | CFO | 1,701 0.0021% | $25.04 | $42,593 | -72.17% | ||
| 2023-06-15 | Sale | director | 2,500 0.003% | $28.24 | $70,600 | -74.85% | ||
| 2023-06-09 | Sale | CEO | 31,279 0.0397% | $30.72 | $960,928 | -75.29% | ||
| 2023-06-09 | Sale | President | 5,000 0.0064% | $30.82 | $154,096 | -75.29% | ||
| 2023-06-02 | Sale | CFO | 500 0.0006% | $31.00 | $15,500 | -75.42% | ||
| 2023-06-01 | Sale | CFO | 2,701 0.0033% | $30.57 | $82,570 | -74.75% | ||
| 2023-05-15 | Sale | CEO | 70,447 0.0886% | $34.55 | $2.43M | -75.34% | ||
| 2023-05-15 | Sale | President | 21,015 0.0264% | $34.55 | $726,003 | -75.34% | ||
| 2023-05-15 | Sale | CFO | 21,401 0.0269% | $34.55 | $739,338 | -75.34% | ||
| 2023-05-15 | Sale | SVP, GC & Secretary | 21,401 0.0269% | $34.55 | $739,338 | -75.34% |
Insider Historical Profitability
| Foley Mark J | CEO | 1015468 0.9728% | $3.07 | 3 | 5 | +21.46% |
| Browne L Daniel | CEO and President | 151193 0.1448% | $3.07 | 1 | 16 | +60.04% |
| Rankin Aubrey | President, Innovation & Tech | 95463 0.0914% | $3.07 | 1 | 10 | +14.59% |
| SILVERNAIL LAUREN P | CFO & CBO | 65497 0.0627% | $3.07 | 1 | 8 | +53.99% |
| Russell Angus C. | director | 26913 0.0258% | $3.07 | 1 | 0 | +9.71% |
Institutional Investor Ownership
| Capital World Investors | $68.61M | 13.35 | 13.95M | +16.81% | +$9.87M | 0.01 | |
| BlackRock | $35.98M | 7 | 7.31M | -1.89% | -$693,188.65 | <0.01 | |
| Franklin Templeton Investments | $30.91M | 6.02 | 6.28M | +32.3% | +$7.55M | 0.01 | |
| The Vanguard Group | $26.56M | 5.17 | 5.4M | +6.49% | +$1.62M | <0.0001 | |
| Palo Alto Investors Lp | $25.82M | 5.02 | 5.25M | +0.2% | +$52,742.40 | 2.91 |